Combination Therapy

FASLODEX has proven results as a combination therapy in multiple trials1*

Lisa, Phyllis, and Veronica are:

Lisa shares some characteristics with patients in the MONALEESA-3 Trial1‡

  • Disease recurred >2 years after cessation of adjuvant endocrine therapy
  • Bone and liver metastases

The MONALEESA-3 Trial studied FASLODEX + ribociclib. FASLODEX may be right for your patients like Lisa.

Phyllis shares some characteristics with patients in the PALOMA-3§ Trial2

  • Disease progressed after aromatase inhibitor (AI) therapy
  • Bone-only metastases

The PALOMA-3 Trial studied FASLODEX + palbociclib. FASLODEX may be right for your patients like Phyllis.

Veronica shares some characteristics with patients in the MONARCH 2 Trial2

  • Primary endocrine therapy resistance
  • Visceral metastases

The MONARCH 2 Trial studied FASLODEX + abemaciclib. FASLODEX may be right for your patients like Veronica.

*In combination with palbociclib or abemaciclib.

Individual results may vary. This is not a real patient. This representation was not designed to reflect efficacy for an individual patient subgroup.

MONALEESA-3 was a Phase 3, randomized, double-blind, placebo-controlled, international study of FASLODEX 500 mg on Days 1, 15, 29 and once monthly thereafter in combination with ribociclib 600 mg taken orally, once daily for 21 consecutive days followed by 7 days off in 726 women with HR-positive, HER2-negative ABC or mBC.1,2

§PALOMA-3 was a phase 3, international, randomized, double-blind, parallel-group, multicenter study of FASLODEX 500 mg in combination with palbociclib 125 mg vs FASLODEX plus placebo in 521 women with HR-positive, HER2-negative ABC whose disease progressed on or after prior endocrine therapy.2,3

MONARCH 2 was a phase 3, randomized, double-blind, placebo-controlled, multicenter, international study of FASLODEX 500 mg in combination with abemaciclib 150 mg vs FASLODEX plus placebo in 669 women with HR-positive, HER2-negative ABC or metastatic breast cancer (mBC) that progressed while receiving prior endocrine therapy in the neoadjuvant, adjuvant, or early-line metastatic setting.2,4

References: 1. Slamon DJ, Neven P, Chia S, et al. Phase Ill randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. 2. FASLODEX® (fulvestrant) [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; 2019. 3. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439. 4. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884.